Difference between revisions of "EP Measure Specifications Overview"

<table border=1 cellpadding=2 cellspacing=0 width=1150 style='border-collapse:

collapse;table-layout:fixed;width:962pt'>

 

<tr><td >Quality Measure Wiki</td><td >Submission Date</td>

   <td height=20 class=xl65 width=200>Measure Files</td>

   <td class=xl66 style='border-top:none;border-left:none'>Developer</td>

   <td class=xl67 width=200 style='border-top:none;border-left:none;width:251pt'>Title</td>

   <td class=xl70 width=300>Description</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Asthma Assessment</td>

   <td class=xl70 width=300>Percentage of patients aged 5 through 40 years with a diagnosis of asthma and who have been seen for at least 2 office visits, who were evaluated during at least one office visit within 12 months for the frequency (numeric) of daytime and nocturnal asthma symptoms.</td>

 

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Appropriate Testing for Children with Pharyngitis</td>

   <td class=xl70 width=300>The percentage of children 2–18 years of age who were diagnosed with Pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement</td>

   <td class=xl70 width=300>The percentage of adolescent and adult patients with a new episode of alcohol and other drug (AOD) dependence who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis and who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)</td>

   <td class=xl70 width=300>Percentage of patients, regardless of age, who gave birth during a 12-month period who were screened for HIV infection during the first or second prenatal visit.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Hypertension: Blood Pressure Measurement</td>

   <td class=xl70 width=300>Percentage of patient visits for patients aged 18 years and older with a diagnosis of hypertension who have been seen for at least 2 office visits, with blood pressure (BP) recorded.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Prenatal Care: Anti-D Immune Globulin</td>

   <td class=xl70 width=300>Percentage of D (Rh) negative, unsensitized patients, regardless of age, who gave birth during a 12-month period who received anti-D immune globulin at 26-30 weeks gestation.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Controlling High Blood Pressure</td>

   <td class=xl70 width=300>The percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose BP was adequately controlled during the measurement year.</td>   

   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>2011_EHR_Downloadable_Resource_Table-Release_Notes_July2010-070110.pdf (page 69) https://www.cms.gov/PQRI/Downloads/EHR_Docs_for_Eligible_Professionals_080610.zip </td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>NQF Measure #0022: Drugs to be Avoided in the Elderly   

   <td class=xl70 width=300>Percentage of patients ages 65 years and older who received at least one drug to be avoided in the elderly and/or two different drugs to be avoided in the elderly in the measurement period.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Weight Assessment and Counseling for Children and Adolescents</td>

   <td class=xl70 width=300>The percentage of patients 2-17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of BMI percentile documentation, counseling for nutrition and counseling for physical activity during the measurement year.</td>

     <td class=xl70 width=200>Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies</td>

   <td class=xl70 width=300>The percentage of patients 18 years of age and older who were current smokers or tobacco users, who were seen by a practitioner during the measurement year and who received advice to quit smoking or tobacco use or whose practitioner recommended or discussed smoking or tobacco use cessation medications, methods or strategies.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Preventive Care and Screening Measure Pair: a.Tobacco Use Assessment</td>

   <td class=xl70 width=300>Percentage of patients aged 18 years or older who have been seen for at least 2 office visits, who were queried about tobacco use one or more times within 24 months.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Preventive Care and Screening Measure Pair: b.Tobacco Cessation Intervention</td>

   <td class=xl70 width=300>Percentage of patients aged 18 years and older identified as tobacco users within the past 24 months who received cessation intervention.</td>

<tr><td >[http://vistapedia.net/index.php?title=2011_EHR_Quality_Measure_Spec_0031  0031 - wiki page] </td><td >Phase II </td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Breast Cancer Screening</td>

   <td class=xl70 width=300>The percentage of women 40–69 years of age who had a mammogram to screen for breast cancer.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Cervical Cancer Screening</td>

   <td class=xl70 width=300>The percentage of women 21-64 years of age who received one or more Pap tests to screen for cervical cancer.</td>

<tr><td >[http://vistapedia.net/index.php?title=2011_EHR_Quality_Measure_Spec_0033  0033 - wiki page] </td><td >1-Nov-10 </td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Chlamydia Screening for Women</td>

   <td class=xl70 width=300>The percentage of women 15-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.</td>

<tr><td >[http://vistapedia.net/index.php?title=2011_EHR_Quality_Measure_Spec_0034  0034 - wiki page] </td><td >Phase II </td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Colorectal Cancer Screening</td>

   <td class=xl70 width=300>The percentage of adults 50–75 years of age who had appropriate screening for colorectal cancer.</td>

<tr><td >[http://vistapedia.net/index.php?title=2011_EHR_Quality_Measure_Spec_0036  0036 - wiki page] </td><td >1-Nov-10 </td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Use of Appropriate Medications for Asthma</td>

   <td class=xl70 width=300>The percentage of patients 5-50 years of age during the measurement year who were identified as having persistent asthma and were appropriately prescribed medication during the measurement year. Report three age stratifications (5-11 years, 12-50 years, and total).</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Childhood immunization Status</td>

   <td class=xl70 width=300>The percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV); one measles, mumps and rubella (MMR); two H influenza type B (HiB); three hepatitis B (Hep B), one chicken pox (VZV); four pneumococcal conjugate (PCV); two hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday. The measure calculates a rate for each vaccine and two separate combination rates.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Preventive Care and Screening: Influenza Immunization for Patients &#8805; 50 Years Old</td>

   <td class=xl70 width=300>Percentage of patients aged 50 years and older who received an influenza immunization during the flu season (September through February).</td>

<tr><td >[http://vistapedia.net/index.php?title=2011_EHR_Quality_Measure_Spec_0043  0043 - wiki page] </td><td >Phase II </td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Pneumonia Vaccination Status for Older Adults</td>

   <td class=xl70 width=300>The percentage of patients 65 years of age and older as of January 1 of the measurement year who have ever received a pneumococcal vaccine.</td>

<tr><td >[http://vistapedia.net/index.php?title=2011_EHR_Quality_Measure_Spec_0047  0047 - wiki page] </td><td >1-Nov-10 </td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Asthma Pharmacologic Therapy</td>

   <td class=xl70 width=300>Percentage of patients aged 5 through 40 years with a diagnosis of mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Low Back Pain: Use of Imaging Studies</td>

   <td class=xl70 width=300>The percentage of patients with a primary diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of diagnosis.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Diabetes: Eye Exam</td>

   <td class=xl70 width=300>The percentage of patients 18–75 years of age with diabetes (type 1 or type 2) who had a retinal or dilated eye exam or a negative retinal exam (no evidence of retinopathy) by an eye care professional .</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Diabetes: Foot Exam</td>

   <td class=xl70 width=300>The percentage of patients aged 18-75 years with diabetes (type 1 or type 2) who had a foot exam (visual inspection, sensory exam with monofilament, or pulse exam).</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Diabetes: HbA1c Poor Control</td>

   <td class=xl70 width=300>The percentage of patients 18–75 years of age with diabetes (type 1 or type 2) who had HbA1c &gt;9.0%.</td>

   <td class=xl70 width=200>Diabetes: Blood Pressure Management</td>

   <td class=xl70 width=300>The percentage of patients 18–75 years of age with diabetes (type 1 or type 2) who had BP &lt;140/90 mmHg.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Diabetes: Urine Screening</td>

   <td class=xl70 width=300>The percentage of patients 18–75 years of age with diabetes (type 1 or type 2) who had a nephropathy screening test or evidence of nephropathy .</td>   

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Diabetes: LDL Management &amp; Control</td>

   <td class=xl70 width=300>The percentage of patients 18–75 years of age with diabetes (type 1 or type 2) who had LDL-C &lt;100mg/dL.</td>

   <td class=xl70 width=200>Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD</td>

   <td class=xl70 width=300>Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed oral antiplatelet therapy.</td>

   <td class=xl70 width=200>Ischemic Vascular Disease (IVD): Use of Aspirin or another Antithrombotic</td>

   <td class=xl70 width=300>The percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1–November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and who had documentation of use of aspirin or another antithrombotic during the measurement year.</td>

   <td class=xl70 width=200>Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)</td>

   <td class=xl70 width=300>Percentage of patients aged 18 years and older with a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Ischemic Vascular Disease (IVD): Blood Pressure Management</td>

   <td class=xl70 width=300>The percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1–November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and whose most recent blood pressure is in control (&lt;140/90 mmHg).</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol</td>

   <td class=xl70 width=300>Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed a lipid-lowering therapy (based on current ACC/AHA guidelines).</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control</td>

   <td class=xl70 width=300>The percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1–November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and who had a complete lipid profile performed during the measurement year and whose LDL-C was &lt;100 mg/dL.</td>

<tr><td >[http://vistapedia.net/index.php?title=2011_EHR_Quality_Measure_Spec_81  81 - wiki page] </td><td >1-Nov-10 </td>

   <td class=xl70 width=200>Heart Failure (HF) : Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)</td>

   <td class=xl70 width=300>Percentage of patients aged 18 years and older with a diagnosis of heart failure and LVSD (LVEF &lt; 40%) who were prescribed ACE inhibitor or ARB therapy.</td>

   <td class=xl70 width=200>Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)</td>

<td class=xl70 width=300>Percentage of patients aged 18 years and older with a diagnosis of heart failure who also have LVSD (LVEF &lt; 40%) and who were prescribed beta-blocker therapy.</td>

   <td class=xl70 width=200>Heart Failure (HF) : Warfarin Therapy Patients with Atrial Fibrillation</td>

<td class=xl70 width=300>Percentage of all patients aged 18 and older with a diagnosis of heart failure and paroxysmal or chronic atrial fibrillation who were prescribed warfarin therapy.</td>

   <td class=xl70 width=200>Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation</td>

<td class=xl70 width=300>Percentage of patients aged 18 years and older with a diagnosis of POAG who have been seen for at least 2 office visits, who have an optic nerve head evaluation during one or more office visits within 12 months.</td>

   <td class=xl70 width=200>Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy</td>

<td class=xl70 width=300>Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months.</td>

   <td class=xl70 width=200>Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care</td>

<td class=xl70 width=300>Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the on-going care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Anti&#8208;depressant medication management: (a) Effective Acute Phase Treatment, (b)Effective Continuation Phase Treatment</td>

   <td class=xl70 width=300>The percentage of patients 18 years of age and older who were diagnosed with a new episode of major depression, treated with antidepressant medication, and who remained on an antidepressant medication treatment.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Oncology Colon Cancer:  Chemotherapy for Stage

   <td class=xl70 width=300>Percentage of patients aged 18 years and older with Stage IIIA through IIIC colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Oncology Breast Cancer:  Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer</td>

   <td class=xl70 width=300>Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Prostate Cancer:  Avoidance of Overuse of Bone

   <td class=xl70 width=300>Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Adult Weight Screening and Follow-Up</td>

   <td class=xl70 width=300>Percentage of patients aged 18 years and older with a calculated BMI in the past six months or during the current visit documented in the medical record AND if the most recent BMI is outside parameters, a follow-up plan is documented.</td>

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Diabetes: HbA1c Control (&lt;8%)</td>

   <td class=xl70 width=300>The percentage of patients 18–75 years of age with diabetes (type 1 or type 2) who had HbA1c &lt;8.0%.</td>

   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>2011_EHR_Downloadable_Resource_Table-Release_Notes_July2010-070110.pdf (page 69) https://www.cms.gov/PQRI/Downloads/EHR_Docs_for_Eligible_Professionals_080610.zip  

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older  </td>

   <td class=xl70 width=300> Percentage of female patients aged 65 years and older who have a central dual-energy X-ray absorptiometry (DXA) measurement ordered or performed at least once since age 60 or pharmacologic therapy prescribed within 12 months .

   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>2011_EHR_Downloadable_Resource_Table-Release_Notes_July2010-070110.pdf (page 69) https://www.cms.gov/PQRI/Downloads/EHR_Docs_for_Eligible_Professionals_080610.zip  

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'> Advance Care Plan  </td>

   <td class=xl70 width=300>Percentage of patients aged 65 years and older who have an advance care plan or surrogate decision maker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan.

 

<tr><td >[http://vistapedia.net/index.php?title=2011_EHR_Quality_Measure_Spec_48  48 - wiki page] </td><td >Phase II </td>

   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>2011_EHR_Downloadable_Resource_Table-Release_Notes_July2010-070110.pdf (page 69) https://www.cms.gov/PQRI/Downloads/EHR_Docs_for_Eligible_Professionals_080610.zip  

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women  Aged 65 Years and Older </td>

   <td class=xl70 width=300>Percentage of female patients aged 65 years and older who were assessed for the presence or absence of urinary incontinence within 12 months.

   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>2011_EHR_Downloadable_Resource_Table-Release_Notes_July2010-070110.pdf (page 69) https://www.cms.gov/PQRI/Downloads/EHR_Docs_for_Eligible_Professionals_080610.zip  

   <td class=xl70 width=200 style='border-top:none;border-left:none;width:251pt'>Drugs to be Avoided in the Elderly</td>

   <td class=xl70 width=300>Percentage of patients ages 65 years and older who received at least one drug to be avoided in the elderly and/or two different drugs to be avoided in the elderly in the measurement period.